Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Exploring the effects of botulinum toxin type A injections on depression

Exploring the effects of botulinum toxin type A injections on depression Depression is a common condition affecting over 300 million people around the world. There are many known treatments for depression, however in long-lasting, moderate-to-severe conditions, depression can, in some cases, lead to suicide. The facial feedback hypothesis states that facial musculature not only expresses mood states, but also regulates them. By contracting a specific muscle, humans can create an emotion and, conversely, by relaxing those muscles, they can minimise an emotion. Botulinum toxin type A is a neurotoxin which acts as a blocking agent, leading to muscles being temporarily weakened or paralysed. Numerous studies have shown the link between a reduction in depressive symptoms and the treatment of the glabella with botulinum toxin type A injections. The manufacturer of Botox (Allergan) has continued with this research and, in 2017, it announced data from a phase 2 study supporting the advancement of botulinum toxin type A for the treatment of major depressive disorder. The company will now be moving the drug forward to a phase 3 programme for a potential new treatment for patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Aesthetic Nursing Mark Allen Group

Exploring the effects of botulinum toxin type A injections on depression

Journal of Aesthetic Nursing , Volume 7 (6): 3 – Jul 2, 2018

Loading next page...
 
/lp/mark-allen-group/exploring-the-effects-of-botulinum-toxin-type-a-injections-on-pW19schvUb
Publisher
Mark Allen Group
Copyright
Copyright © 2018 MA Healthcare Limited
ISSN
2050-3717
eISSN
2052-2878
DOI
10.12968/joan.2018.7.6.315
Publisher site
See Article on Publisher Site

Abstract

Depression is a common condition affecting over 300 million people around the world. There are many known treatments for depression, however in long-lasting, moderate-to-severe conditions, depression can, in some cases, lead to suicide. The facial feedback hypothesis states that facial musculature not only expresses mood states, but also regulates them. By contracting a specific muscle, humans can create an emotion and, conversely, by relaxing those muscles, they can minimise an emotion. Botulinum toxin type A is a neurotoxin which acts as a blocking agent, leading to muscles being temporarily weakened or paralysed. Numerous studies have shown the link between a reduction in depressive symptoms and the treatment of the glabella with botulinum toxin type A injections. The manufacturer of Botox (Allergan) has continued with this research and, in 2017, it announced data from a phase 2 study supporting the advancement of botulinum toxin type A for the treatment of major depressive disorder. The company will now be moving the drug forward to a phase 3 programme for a potential new treatment for patients.

Journal

Journal of Aesthetic NursingMark Allen Group

Published: Jul 2, 2018

There are no references for this article.